Contract drug manufacturer Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for in $1.2 billion in cash, to help expand its gene-therapy manufacturing capabilities. Paragon provides supplies for gene-therapy drugmakers, manufacturing the so-called viral vectors that are used to deliver the gene replacements to their targets. It is backed by private-equity firms Camden Partners and NewSpring Capital.

Source: Wall Street Journal April 15, 2019 12:22 UTC